News Releases

Positioned to Expand Patient Access and Accelerate Impact in Rare Diseases PARMA, Italy & FRAMINGHAM, Mass. --(BUSINESS WIRE)--Jun. 11, 2026-- Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, today announced the completion of its acquisition

Presentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children aged 2–11 living with HAE FRAMINGHAM, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 28,

Highlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bn Acquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s

FRAMINGHAM, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 8, 2026-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference, April 15, 2026, at 10:15 a.m.

FRAMINGHAM, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 2, 2026-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista’s Board of Directors granted five newly-hired employees inducement options to purchase an aggregate of 66,375 shares of

Interim data show sebetralstat enables early, effective treatment of hereditary angioedema (HAE) attacks in children with favorable safety and tolerability FRAMINGHAM, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 30, 2026-- KalVista Pharmaceuticals, Inc.

$49.1 million global net product revenue of EKTERLY ® (sebetralstat) for the eight months ended December 31, 2025 1,702 patient start forms received in the US from launch through end of February, reflecting continued rapid adoption of first and only oral on-demand treatment for hereditary

New interim data from the KONFIDENT-KID trial evaluating sebetralstat in children aged 2-11 accepted for late-breaking oral presentation FRAMINGHAM, Mass. & SALISBURY, England--( BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that five abstracts, including one

FRAMINGHAM, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 18, 2026-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) will host a conference call and webcast on Wednesday, March 25, 2026, at 8:30 a.m. ET to review the Company’s eight months fiscal year 2025 financial results and provide a

FRAMINGHAM, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 4, 2026-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Compensation Committee of KalVista’s Board of Directors granted one newly-hired employee inducement options to purchase an aggregate of 6,750 shares of